<DOC>
	<DOCNO>NCT01434498</DOCNO>
	<brief_summary>This Phase 2 Randomized , Double-Blind , Placebo-Controlled Study GS-5885 , GS-9451 , Tegobuvir Ribavirin ; GS-5885 , GS-9451 Tegobuvir ; GS-5885 , GS-9451 Ribavirin Interferon Ineligible Intolerant Subjects Chronic Genotype 1a 1b HCV Infection .</brief_summary>
	<brief_title>GS-5885 , GS-9451 , Tegobuvir Ribavirin ( RBV ) Interferon Ineligible Intolerant Subjects With Chronic Genotype 1a 1b Hepatitis C Virus ( HCV ) Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Ledipasvir</mesh_term>
	<criteria>Adult subject 18 old chronic HCV infection Liver biopsy result ( performed 3 year prior Screening ) indicate absence cirrhosis Monoinfection HCV genotype 1a 1b Interferon ineligible intolerant Body mass index ( BMI ) 18 40 kg/m2 Use highly effective contraception method female childbearing potential sexually active male Screening laboratory value within define threshold Has expose investigational drug device within 30 day Screening visit Able comply dose instruction study drug administration able complete study schedule assessment Prior treatment HCV directacting antiviral ( whether approve experimental ) Decompensated liver disease cirrhosis Coinfection human immunodeficiency virus ( HIV ) , hepatitis B virus ( HBV ) , another HCV genotype History difficulty blood collection and/or poor venous access Pregnant nursing female male pregnant female partner Chronic liver disease nonHCV etiology Suspicion hepatocellular carcinoma Clinicallyrelevant drug abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>HCV</keyword>
	<keyword>Rapid Virologic Response</keyword>
	<keyword>Sustained Virologic Response</keyword>
	<keyword>Direct Acting Antiviral</keyword>
	<keyword>Combination Therapy</keyword>
	<keyword>Tegobuvir</keyword>
	<keyword>Treatment na√Øve</keyword>
	<keyword>HCV RNA</keyword>
	<keyword>Polymerase inhibitor</keyword>
	<keyword>Protease inhibitor</keyword>
	<keyword>Interferon intolerant</keyword>
	<keyword>Interferon ineligible</keyword>
	<keyword>GS-9190</keyword>
	<keyword>GS-9451</keyword>
	<keyword>GS-5885</keyword>
</DOC>